Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Non-alcoholic Fatty Liver Disease*/blood ; Non-alcoholic Fatty Liver Disease*/complications ; Non-alcoholic Fatty Liver Disease*/pathology ; Liver Cirrhosis*/blood ; Liver Cirrhosis*/diagnosis ; Liver Cirrhosis*/pathology ; Liver Cirrhosis*/etiology ; Mean Platelet Volume*; Biomarkers/blood ; Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Blood Platelets

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Accurate assessment of liver fibrosis is essential for the prognosis and management of NAFLD. Mean platelet volume (MPV), an index of platelet activation, has been associated with liver fibrosis in various chronic liver diseases; however, its role in NAFLD remains uncertain.
Methods: This study analyzed data from 70,830 patients with NAFLD who underwent a comprehensive health examination between 2015 and 2019. Patients were stratified into three groups based on the fibrosis-4 (FIB-4) index: low (<1.30), indeterminate (1.30-2.67), and high (>2.67). We evaluated the differences in MPV among these groups and analyzed the association between MPV and the FIB-4 index.
Results: MPV varied significantly across the three groups categorized by the FIB-4 index (p < 0.001). Additionally, a weak but statistically significant positive correlation was observed between MPV and the FIB-4 index (rho =  0.170, p <  0.001). Multivariable linear regression adjusted for multiple covariates showed that MPV remained significantly associated with the FIB-4 index (β =  0.01, p <  0.001).
Conclusions: MPV may serve as a supplementary non-invasive marker for assessing liver fibrosis in patients with NAFLD. Further studies are required to validate these findings and explore the utility of MPV in conjunction with other non-invasive markers.
(Copyright: © 2025 Cho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

The authors have declared that no competing interests exist.

Hepatology. 2023 Apr 1;77(4):1335-1347. (PMID: 36626630)
Platelets. 2013;24(3):194-9. (PMID: 22646469)
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. (PMID: 19523535)
PLoS One. 2020 Jan 9;15(1):e0227544. (PMID: 31917827)
Gastroenterology. 1999 Jun;116(6):1413-9. (PMID: 10348825)
J Hepatol. 2008 May;48(5):835-47. (PMID: 18334275)
Abdom Radiol (NY). 2016 Feb;41(2):265-72. (PMID: 26867908)
Eur J Endocrinol. 2020 Sep;183(3):R57-R73. (PMID: 32508312)
Acta Gastroenterol Belg. 2020 Jul-Sep;83(3):419-425. (PMID: 33094589)
Transl Res. 2021 May;231:24-38. (PMID: 33171266)
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. (PMID: 29307986)
Dig Liver Dis. 2002 Jul;34(7):516-22. (PMID: 12236486)
J Thromb Haemost. 2020 Jun;18(6):1256-1267. (PMID: 32108994)
Hepatology. 2006 Jun;43(6):1317-25. (PMID: 16729309)
J Clin Lab Anal. 2011;25(3):162-5. (PMID: 21567462)
Hepatol Res. 2024 Jun;54(6):551-561. (PMID: 38133526)
Medicina (Kaunas). 2022 May 06;58(5):. (PMID: 35630058)
Blood Adv. 2018 Mar 13;2(5):470-480. (PMID: 29490978)
Gastroenterology. 2014 Dec;147(6):1378-92. (PMID: 25173753)
J Clin Invest. 2010 Jul;120(7):2379-94. (PMID: 20577048)

0 (Biomarkers)

Date Created: 20250218 Date Completed: 20250508 Latest Revision: 20250508

20260130

PMC11835247

10.1371/journal.pone.0318847

39964985